NCT04523480View on ClinicalTrials.gov

Testopel ® vs. Generic Testosterone Pellets.

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Hypogonadism
Interventions
DRUG

Testopel 75mg Drug Implant

75 mg Testosterone pellets administered subcutaneously.

DRUG

Testopel 100mg Drug Implant

100 mg Testosterone pellets administered subcutaneously.

DRUG

Testopel 200mg Drug Implant

200 mg Testosterone pellets administered subcutaneously.

Trial Locations (1)

33136

University of Miami, Department of Urology, Miami

Sponsors

Collaborators (1)

Empower Research Inc
All Listed Sponsors
collaborator

Empower Research Inc

INDUSTRY

lead

University of Miami

OTHER